ReviewExpert opinion on drug discovery2010
Challenges and opportunities for new protein crystallization strategies in structure-based drug design.
Review in Expert opinion on drug discovery, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Chimeric Approach to Identify Molecular Determinants of Nicotinic Acetylcholine Receptors.International journal of molecular sciences · 2026Review
- How many crystal structures do you need to trust your docking results?bioRxiv : the preprint server for biology · 2025Article
- Cryo-electron microscopy-based drug design.Frontiers in molecular biosciences · 2024Review
- μMap Photoproximity Labeling Enables Small Molecule Binding Site Mapping.Journal of the American Chemical Society · 2023Article
- Preparation and Characterization of Metal-Organic Framework Coatings for Improving Protein Crystallization Screening.Nanomaterials (Basel, Switzerland) · 2023Article
- Getting to the bottom of lncRNA mechanism: structure-function relationships.Mammalian genome : official journal of the International Mammalian Genome Society · 2022Review
- Targeting the C-Terminal Domain Small Phosphatase 1.Life (Basel, Switzerland) · 2020Review
- Rigorous sampling of docking poses unveils binding hypothesis for the halogenated ligands of L-type Amino acid Transporter 1 (LAT1).Scientific reports · 2019Article
- Park 7: A Novel Therapeutic Target for Macrophages in Sepsis-Induced Immunosuppression.Frontiers in immunology · 2018Review
- Survey of Predictors of Propensity for Protein Production and Crystallization with Application to Predict Resolution of Crystal Structures.Current protein & peptide science · 2018Article
- Molecular basis for inhibition of AcrB multidrug efflux pump by novel and powerful pyranopyridine derivatives.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Formation of crystal-like structures and branched networks from nonionic spherical micelles.Scientific reports · 2015Article
- Crystal Structures and Structure-Activity Relationships of Imidazothiazole Derivatives as IDO1 Inhibitors.ACS medicinal chemistry letters · 2014Article
- Lessons from high-throughput protein crystallization screening: 10 years of practical experience.Expert opinion on drug discovery · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Structure-based drug design (SBDD) has emerged as a valuable pharmaceutical lead discovery tool, showing potential for accelerating the discovery process,while reducing developmental costs and boosting potencies of the drug that is ultimately selected. SBDD is an iterative, rational, lead compound sculpting process that involves both the synthesis of new derivatives and the evaluation of their binding to the target structure either through computational docking or elucidation of the target structure as a complex with the lead compound. This method heavily relies on the production of high resolution(< 2 Å) 3D structures of the drug target, obtained through X-ray crystallographic analysis, in the presence or absence of the drug candidate.The lack of generalized methods for high quality crystal production is still a major bottleneck in the process of macromolecular crystallization. This review provides a brief introduction to SBDD and describes several macromolecular crystallization strategies, with an emphasis on advances and challenges facing researchers in the field today. Recent trends in the development of more universal macromolecular crystallization techniques, particularly nucleation-based techniques that are applicable to both soluble and integral membrane proteins, are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.